Clinical Trial Update: Octreotide LAR in the Induction of Immunologic Response in NENs Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating octreotide LAR for inducing immunologic response in neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Octreotide LAR (octreotide long-acting release)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED